Earnings

Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate

Nov 5, 2026 · 07:50 AM ET· updated 2h ago

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of $(0.04) per share

Why It Matters

Lexicon lost less money than experts thought it would this quarter. When a company loses less than people expected, that is good news to watch.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LXRX1.60

+0.11 (+7.77%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.